These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32845591)

  • 1. Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
    Kircik L; Stein Gold L; Teng J; Moore A; Cantrell W; Alonso-Llamazares J; Koo J
    J Drugs Dermatol; 2020 Aug; 19(8):723-732. PubMed ID: 32845591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
    Kircik LH; Schlesinger TE; Tanghetti E
    J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
    Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
    Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
    Petersen B; Lebwohl M
    J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
    Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
    J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
    Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
    Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
    J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
    Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
    J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
    J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?
    Giovene GL; Giacomelli L;
    G Ital Dermatol Venereol; 2018 Dec; 153(6):872-876. PubMed ID: 30261718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.
    Menter A; Gold LS; Koo J; Villumsen J; Rosén M; Lebwohl M
    Skinmed; 2017; 15(2):119-124. PubMed ID: 28528605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis.
    Amat-Samaranch V; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):423-432. PubMed ID: 32243212
    [No Abstract]   [Full Text] [Related]  

  • 14. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
    Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
    J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
    Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
    J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
    Warren RB; Gold M; Gooderham M; Kircik LH; Lacour JP; Laws P; Liljedahl M; Lynde C; Mørch MH; Sondermann W; Thaçi D
    J Drugs Dermatol; 2021 Apr; 20(4):436-441. PubMed ID: 33852252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
    Foley P; Garrett S; Ryttig L
    Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
    Bagel J; Nelson E; Riley C; Hetzel A
    J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
    Fabbrocini G; Dauden E; Jalili A; Bewley A
    G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.